RE:Persuade me!There are 3 possible outcomes in the next 2.5 months.
1) FDA approves MCNA as is and agrees with the 5 out of 7 Urologists on the advisory panel. We open at $2.50 with a few stops on the way to $7 to $10 per share/
2) FDA approves MCNA with a more narrow scope like Patients unable or unwilling to have their Bladders removed. They would likley be required to do a 2nd FDA phase 3B or Phase 4 trial while we market and sell MCNA. We open at $1.75.
3) FDA says no to already priority reviewed trial data and says we need another Phase 3B trial. My guess would be we would be trading somewhere around where we sit now until a partner to pay for trial comes on board. We open at .25 to .28 cents.
Most companies with Phase 3 complete Oncology products get a valuation 4 to 5 times ours, but that remains to be seen if we stay that way. We have 45mm CDN in cash and a huge WW partner (ex Japan, S. Korea, South Africa, Canada and Mexico) in IPSEN who would likely jump at the chance to partner for the US. So your downside is pretty slim, and upside after approval will be exponential. Good luck with your DD.
beech